Sugi Predict

Sugi Predict / Compounds / SCHEMBL2356419

SCHEMBL2356419

SCHEMBL2356419

CCC1C(C(N)=O)CCCN1CC

nearest known ligand 0.41

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 2/20 0.41
▸ EPHX1 P07099 1/20 0.40
▸ ALDH1A1 P00352 2/20 0.39
▸ L3MBTL1 Q9Y468 1/20 0.37
▸ MAPK1 P28482 1/20 0.35
▸ BCHE P06276 1/20 0.35
▸ HTT P42858 1/20 0.35
▸ LMNA P02545 1/20 0.34
▸ GAA P10253 1/20 0.33
▸ RAB9A P51151 1/20 0.33
▸ PSEN1 P49768 3/20 0.32
▸ PSEN2 P49810 3/20 0.32
▸ APH1B Q8WW43 3/20 0.32
▸ NCSTN Q92542 3/20 0.32
▸ APH1A Q96BI3 3/20 0.32
▸ PSENEN Q9NZ42 3/20 0.32
▸ DRD2 P14416 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7700224 0.84 ALDH1A1 (0.43) SMN1; SMN2ALDH1A1L3MBTL1HTTRAB9A
SCHEMBL27575119 0.76 ALDH1A1 (0.39) SMN1; SMN2ALDH1A1L3MBTL1MAPK1HTT
SCHEMBL1031700 0.74 SMN1; SMN2 (0.46) SMN1; SMN2ALDH1A1L3MBTL1MAPK1BCHE
SCHEMBL1530965 0.74 SMN1; SMN2 (0.46) SMN1; SMN2ALDH1A1L3MBTL1MAPK1BCHE
SCHEMBL4491733 0.74 SMN1; SMN2 (0.46) SMN1; SMN2ALDH1A1L3MBTL1MAPK1BCHE
Hydrochloric Acid SCHEMBL14888080 0.73 SMN1; SMN2 (0.44) SMN1; SMN2ALDH1A1L3MBTL1MAPK1BCHE
Hydrochloric Acid SCHEMBL14311856 0.73 SMN1; SMN2 (0.44) SMN1; SMN2ALDH1A1L3MBTL1MAPK1BCHE
Hydrochloric Acid SCHEMBL3970845 0.73 SMN1; SMN2 (0.44) SMN1; SMN2ALDH1A1L3MBTL1MAPK1BCHE
Hydrochloric Acid SCHEMBL2673112 0.73 SMN1; SMN2 (0.44) SMN1; SMN2ALDH1A1L3MBTL1MAPK1BCHE
Hydrochloric Acid SCHEMBL16110963 0.71 ALDH1A1 (0.33) ALDH1A1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2009102537-A1 INHIBITORS OF CHECKPOINT KINASES MERCK & CO., INC. (US) 2009-08-20 — — WO claimed
JP-2008521903-A — — 2008-06-26 — — JP claimed
EP-1831206-A2 N-SUBSTITUTED BENZIMIDAZOLYL C-KIT INHIBITORS AND COMBINATORIAL BENZIMIDAZOLE LIBRARY OSI Pharmaceuticals, Inc. (US) 2007-09-12 — — EP claimed
WO-2006060381-A2 N-SUBSTITUTED BENZIMIDAZOLYL C-KIT INHIBITORS AND COMBINATORIAL BENZIMIDAZOLE LIBRARY OSI PHARMACEUTICALS, INC. (US) 2006-06-08 — — WO claimed
WO-2002042361-A1 STABLE, CONCENTRATED SOLUTIONS OF POLYANILINE USING AMINES AS GEL INHIBITORS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2002-05-30 — — WO claimed
EP-2681221-A1 TRICYCLIC INHIBITORS OF KINASES AbbVie Inc. (US) 2014-01-08 — — EP disclosed
WO-2012161812-A1 TRICYCLIC INHIBITORS OF KINASES ABBOTT LABORATORIES (US) 2012-11-29 — — WO disclosed
EP-2349252-A2 SYNERGISTIC COMBINATION OF SPHINGOSINE-1-PHOSPHATE RECEPTOR ANTAGONISTS AND ANTIMICROTUBULE AGENTS Exelixis, Inc. (US) 2011-08-03 — — EP disclosed
US-7795290-B2 2-amido-thiazole-based compounds exhibiting ATP-utilizing enzyme inhibitory activity, and compositions, and uses thereof GENENTECH, INC. (US) 2010-09-14 — — US disclosed
WO-2010045601-A2 SYNERGISTIC EFFECTS BETWEEN SPHINGOSINE-1-PHOSPHATE RECEPTOR ANTAGONISTS AND ANTIMICROTUBULE AGENTS EXELIXIS, INC. (US) 2010-04-22 — — WO disclosed
US-20090048313-A1 2-AMIDO-THIAZOLE-BASED COMPOUNDS EXHIBITING ATP-UTILIZING ENZYME INHIBITORY ACTIVITY, AND COMPOSITIONS, AND USES THEREOF GENENTECH, INC. (US) 2009-02-19 — — US disclosed
US-7410988-B2 2-Amido-thiazole-based compounds exhibiting ATP-utilizing enzyme inhibitory activity, and compositions, and uses thereof GENENTECH, INC. (US) 2008-08-12 — — US disclosed
EP-1478437-A1 ACC INHIBITORS Pfizer Products Inc. (US) 2004-11-24 — — EP disclosed
EP-1458374-A2 COMPOUNDS AND USES THEREOF FOR DECREASING ACTIVITY OF HORMONE-SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2004-09-22 — — EP disclosed
EP-1458375-A2 COMPOSITIONS FOR DECREASING ACTIVITY OF HORMONE-SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2004-09-22 — — EP disclosed
WO-2003072197-A1 ACC INHIBITORS PFIZER PRODUCTS INC. (US) 2003-09-04 — — WO disclosed
WO-2003051841-A2 COMPOUNDS AND USES THEREOF FOR DECREASING ACTIVITY OF HORMONE-SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2003-06-26 — — WO disclosed
WO-2003051842-A2 COMPOSITIONS DECREASING ACTIVITY OF HORMONE-SENSITIVE LIPASE NOVO NORDISK A/S (DK) 2003-06-26 — — WO disclosed
EP-1159292-A2 COMPOUNDS HAVING GROWTH HORMONE RELEASING ACTIVITY Administrators of The Tulane Educational Fund (US) 2001-12-05 — — EP disclosed
WO-2000009537-A2 COMPOUNDS HAVING GROWTH HORMONE RELEASING ACTIVITY ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND (US) 2000-02-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090048313-A1 2-AMIDO-THIAZOLE-BASED COMPOUNDS EXHIBITING ATP-UTILIZING ENZYME INHIBITORY ACTIVITY, AND COMPOSITIONS, AND USES THEREOF ATP5ME, ATP5MG, ATP5MK SMN1; SMN2 4020/4885EPHX1 493/4885ALDH1A1 554/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.